- Home
- KROS vs CRMD Comparison
KROS vs CRMD Comparison
Compare KROS & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- CRMD
- Stock Information
- Founded
- KROS 2015
- CRMD 2006
- Country
- KROS United States
- CRMD United States
- Employees
- KROS N/A
- CRMD 82
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- KROS Health Care
- CRMD Health Care
- Exchange
- KROS Nasdaq
- CRMD Nasdaq
- Market Cap
- KROS 565.0M
- CRMD 865.2M
- IPO Year
- KROS 2020
- CRMD 2010
- Fundamental
- Price
- KROS $15.62
- CRMD $11.12
- Analyst Decision
- KROS Buy
- CRMD Strong Buy
- Analyst Count
- KROS 14
- CRMD 8
- Target Price
- KROS $20.56
- CRMD $17.57
- AVG Volume (30 Days)
- KROS 412.4K
- CRMD 4.6M
- Earning Date
- KROS 11-05-2025
- CRMD 10-29-2025
- Dividend Yield
- KROS N/A
- CRMD N/A
- EPS Growth
- KROS N/A
- CRMD N/A
- EPS
- KROS 0.47
- CRMD 0.79
- Revenue
- KROS $232,844,000.00
- CRMD $121,484,498.00
- Revenue This Year
- KROS $5,998.31
- CRMD $404.81
- Revenue Next Year
- KROS N/A
- CRMD $56.11
- P/E Ratio
- KROS $33.74
- CRMD $14.00
- Revenue Growth
- KROS 85820.30
- CRMD 14970.29
- 52 Week Low
- KROS $9.12
- CRMD $5.60
- 52 Week High
- KROS $72.37
- CRMD $17.43
- Technical
- Relative Strength Index (RSI)
- KROS 57.13
- CRMD 34.64
- Support Level
- KROS $15.34
- CRMD $12.73
- Resistance Level
- KROS $15.85
- CRMD $13.83
- Average True Range (ATR)
- KROS 0.45
- CRMD 0.81
- MACD
- KROS -0.02
- CRMD -0.30
- Stochastic Oscillator
- KROS 57.08
- CRMD 0.90
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.